Skip to main content

Advertisement

Table 1 Glycolytic and lipid profile in children with type 2 diabetes before and after lactoferrin treatment

From: Antidiabetic efficacy of lactoferrin in type 2 diabetic pediatrics; controlling impact on PPAR-γ, SIRT-1, and TLR4 downstream signaling pathway

Variables Diabetic patients (N = 30) Controls (N = 30)
Before lactoferrin After lactoferrin
Age 12–17 11 ± 17
Gender
 Male/female 34/26 28/22
BMI (kg/m2) 30.9 ± 2.5a 28.8 ± 2.1 21.2 ± 1.2
Lactoferrin (ng/mL)
 Range 25.6–35.5 44.2–60.5 9.7–19.1
 Mean ± SD 29.73 ± 4.05a 52.35 ± 6.75b 14.01 ± 3.00
FPG (mg/dL)
 Range 197–269a 131–189b 67–110
 Mean ± SD 233 ± 36 130 ± 29 87 ± 22
HbA1c (%) 9.8 ± 1.3a 7.2 ± 1b 5.3 ± 1.5
Insulin range 2.87–14.4a 24.5–35.6b 7.3–10.3
Total cholesterol (mg/dL) 240.5 ± 13.2a 170.6 ± 11.2b 110.67 ± 9.2
Triglycerides (mg/dL) 183.4 ± 6.5a 131 ± 10.2b 75.23 ± 0.92
HDL-C (mg/dL) 27.4 ± 3.5a 38.5 ± 3.3b 42.87 ± 3.2
LDL-C (mg/dL) 176.5 ± 12.5a 105.9 ± 8.2b 53.2 ± 3.2
  1. Values are means ± SDM
  2. BMI body mass index, FPG fasting plasma glucose, HbA1c glycated hemoglobin
  3. aSignificant difference from normal group, at P ≤ 0.05
  4. bSignificant difference from diabetic patients before therapy, at P ≤ 0.05